Contact UsCareers
Top bar

Our approach

Our targeted approach focuses on indications where Notch-pathway activation is a known tumorigenic driver. Using our deep understanding of the Notch pathway, we are developing targeted therapies to address the underlying key drivers of tumor growth in patients where GSI inhibition of Notch may lead to clinical benefit.

 

With possibly the largest database of Notch-activating mutations to inform our efforts, we know that the Notch mutational landscape is diverse in specific cancers that can benefit from a modern screening tool. We have developed a proprietary bioinformatics platform to analyze next-generation sequencing data and identify patients in whom Notch is a tumorigenic driver and therefore may benefit from GSI treatment. We apply our big-data analysis capabilities to identify and confirm patients with Notch-activating mutations who are likely sensitive to GSIs.

bar

Our Pillars

Target

Target

indications in which activated Notch pathway is known to be a tumorigenic driver

Focus

Focus

on indications with high unmet medical need and pursue development in an efficient manner

Expand

Expand

the addressable patient population by developing diagnostic tools that cover all four Notch receptors, genetic mutations and gene rearrangements

- Gary Gordon, MD, PhD, Chief Medical Officer, Ayala Pharmaceuticals

“We are passionate about bringing innovative treatment options to people living with ACC, TNBC, and other rare and aggressive cancers. I’m pleased with the meaningful advances Ayala is making to potentially offer new hope to those living with underserved cancers.”

Our Products

Our scientists utilize unique capabilities in bioinformatics and functional biology to create a Notch-focused patient identification engine that we believe will result in the discovery of additional patients with currently undetected Notch-activating mutations.

Ayala currently has two investigational product candidates in development for a variety of rare and aggressive tumors, including:

Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC)

Recurrent/Metastatic Triple Negative Breast Cancer (R/M TNBC)

Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (R/R T-ALL)

Desmoid Tumors

Multiple Myeloma

Our Products

Our scientists utilize unique capabilities in bioinformatics and functional biology to create a Notch-focused patient identification engine that we believe will result in the discovery of additional patients with currently undetected Notch-activating mutations.

Ayala currently has two product candidates in development for a variety of rare and aggressive tumors including:

Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC)

Recurrent/Metastatic Triple Negative Breast Cancer (R/M TNBC)

Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (R/R T-ALL)

Desmoid Tumors

Multiple Myeloma

Our Products

Our scientists utilize unique capabilities in bioinformatics and functional biology to create a Notch-focused patient identification engine that we believe will result in the discovery of additional patients with currently undetected Notch-activating mutations.

Ayala currently has two product candidates in development for a variety of rare and aggressive tumors including:

Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC)

Recurrent/Metastatic Triple Negative Breast Cancer (R/M TNBC)

Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (R/R T-ALL)

Desmoid Tumors

Multiple Myeloma